Lupus & antiphospholipid syndrome
Comparisons of SLE Disease Activity Score (SLE-DAS) and SLEDAI-2K and classification of disease activity based on the SLE-DAS with reference to patient-reported outcomes
Authors' conclusion
No clear differences were identified in the use of the SLE-DAS over the SLEDAI-2K in assessing PROs in patients with SLE. The classification of disease activity based on the SLE-DAS was validated against several PROs. SLE-DAS and its categories of disease activity effectively explain some of the PROs.
Study context
- Population
- Patients with SLE
- Participants
- 335 patients
- Exposure
- SLE-DAS vs SLEDAI-2K in assessing patient-reported outcomes (PROs)
- Outcome
- Performance of SLE-DAS vs SLEDAI-2K for PROs: generic QoL (SF-36), disease-specific QoL (LupusPRO), symptom burden (SSC), patient global assessment (PtGA) and physician global assessment (PhGA)
Main finding
As reported in the abstract
Predictive performance for PROs
- Mean absolute error, root mean square error, Akaike and Bayesian information criteria comparable for most PROs between SLE-DAS and SLEDAI-2K
- SLEDAI-2K had a higher predictive value for health-related quality of life (QoL) of LupusPRO and patient global assessment (PtGA) than SLE-DAS
Observational data: associations, not effects.
Further findings
SLE-DAS-based classifications of disease activity (low disease activity, Boolean and index-based remission, remission/mild/moderate-severe categories) vs PROs
- Significantly associated with health-related QoL in LupusPRO, SLE Symptom Checklist (SSC) and physician global assessment (PhGA), but not SF-36 or PtGA
Original publication
Comparisons of SLE-DAS and SLEDAI-2K and classification of disease activity based on the SLE-DAS with reference to patient-reported outcomes. Rheumatology (Oxford). Published 21 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →